Feature | March 23, 2015

Study Finds Baroreflex Activation Therapy Effectively Treats Heart Failure

Electrical stimulation of carotid bioreceptor helps correct imbalance in autonomic nervous system

heart failure, BAT, baroreflex activation therapy, William Abraham, CVRx

March 23, 2015 — Results of a clinical trial announced at the American College of Cardiology Annual Scientific Session show a new type of therapy is safe and effective for symptomatic advanced heart failure patients already receiving optimum drug and device therapy. The study also published in the Journal of the American College of Cardiology Heart Failure.

The research team led by William Abraham, M.D., director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, tested whether carotid baroreflex activation therapy (BAT) could safely improve symptoms, exercise capacity and quality of life in patients with New York Heart Association (NYHA) Class III heart failure.

“Heart failure patients experience an imbalance in their autonomic nervous system, which plays a role in disease progression and leads to adverse effects on the heart, blood vessels and kidneys,” Abraham said. “Currently, the optimum drug therapy available is not enough to restore balance for some patients, leaving them highly symptomatic with reduced quality of life. BAT could prove to be an effective added therapy that can help patients feel better.”

BAT is electrical stimulation delivered by an implanted device, similar to a cardiac pacemaker. The tested device from CVRx Inc. has a carotid sinus lead and a pulse generator. Stimulation of the carotid baroreceptor is currently used to treat hypertension that is resistant to drug therapy.

This study enrolled 146 patients with NYHA Class III heart failure and a left ventricular ejection fraction of 35 percent or less at 45 centers in the United States, Canada and Europe. All participants were on guideline-directed medical therapy. The control group of 70 patients received medical therapy alone, while the treatment group of 76 patients received BAT and medical therapy.

After six months, researchers reassessed all of the patients for NYHA Class, quality of life using the Minnesota Living with Heart Failure Questionnaire and exercise capacity using a standardized six-minute hall walk test. Among those assigned to BAT, more than half improved at least one NYHA Class, compared to just a fourth of the control group. The treatment group also reported improved quality of life scores and walked approximately 60 meters farther in six minutes, compared to the control group. Researchers also noted favorable changes in biomarkers among those treated with BAT.

The team reported the device was safely implanted with few complications and no adverse effects. The risk of unfavorable cardiovascular or neurological events over the six-month trial period was the same as similar device-based therapies.

“This is promising news for the nearly 5 million Americans living with heart failure,” Abraham said. “If these findings are confirmed in larger studies, BAT could be a new option for treating advanced stages of the disease."

While it was not intended to evaluate clinical outcomes, Abraham said results from this study support the notion that BAT can reduce heart failure hospitalizations and the number of days hospitalized. However, further research is needed to confirm that.

For more information: www.heartfailure.onlinejacc.org

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init